Clinical Trials Directory

Trials / Conditions / Lenvatinib

Lenvatinib

22 registered clinical trials studyying Lenvatinib — 13 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingRegorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial
NCT07514429
Ju Hyun ShimPhase 2
Not Yet RecruitingConstruction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellula
NCT07417800
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityN/A
Not Yet RecruitingDisitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
NCT07159217
Peking Union Medical College HospitalPhase 2
RecruitingTACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
NCT06740370
Sun Yat-sen UniversityN/A
RecruitingThe Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carc
NCT06609850
Sun Yat-sen UniversityN/A
RecruitingHAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of
NCT06632093
First Hospital of China Medical University—
RecruitingAblation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
NCT06550921
Sun Yat-sen UniversityN/A
RecruitingbTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
NCT06061276
Sun Yat-sen UniversityN/A
RecruitingbTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
NCT06070636
Sun Yat-sen UniversityN/A
CompletedLenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC
NCT06435013
Sun Yat-sen University—
RecruitingLenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage I
NCT05920863
Zhejiang Cancer HospitalPhase 2
Not Yet RecruitingPhase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thromb
NCT05286320
National Taiwan University HospitalPhase 1 / Phase 2
Active Not RecruitingThe Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Bio
NCT07233759
National Taiwan University Hospital—
RecruitingMicrowave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
NCT05444478
Sun Yat-sen UniversityN/A
UnknownStudy of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
NCT04911959
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 1 / Phase 2
TerminatedPembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
NCT04955743
Yale UniversityPhase 2
UnknownTislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Local
NCT05156788
Shanghai Zhongshan HospitalPhase 2
CompletedPhase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC
NCT04791176
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2
UnknownClinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizuma
NCT05131698
Cancer Hospital of Guangxi Medical UniversityEARLY_Phase 1
Active Not RecruitingPhase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Rese
NCT04669496
Shanghai Zhongshan HospitalPhase 2 / Phase 3
CompletedHAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
NCT06631326
First Hospital of China Medical University—
RecruitingHAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
NCT06333561
Sun Yat-sen University—